Gilteritinib(Xospata)

Highly Selective, Targeted Inhibition.
Dual Mechanisms, Synergistic Effects.

WhatsApp

To ensure medication safety, consult customer service for free before purchasing. Returns/exchanges are not accepted except for quality issues.

Authentic

Guarantee

Fast Delivery

Privacy

Gilteritinib Drug News

Gilteritinib, a targeted drug for acute myeloid leukemia, has received conditional approval in China

Asteras Pharmaceuticals recently announced that the National Medical Products Administration (NMPA) of China has conditionally approved XOSPATA® (gite···【Read More】
Update: 11 Mar,2026Source: Haiou HealthViews: 72
Xospata has been accepted by the NMPA for the treatment of relapsed or refractory FLT3 mutation-posi

Japanese pharmaceutical company Astellas recently announced that the NMPA of China has accepted its New Drug Application (NDA) for the targeted antica···【Read More】
Update: 11 Mar,2026Source: Haiou HealthViews: 72
Xospata (gilteritinib) Drug Guide

The U.S. Food and Drug Administration (FDA) today approved Xospata (gilteritinib) tablets for the treatment of adult patients with relapsed or refract···【Read More】
Update: 11 Mar,2026Source: Haiou HealthViews: 72